Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 10:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Locally Recurrent Prostate Carcinoma Clear all
Completed Phase 1 Interventional Results available

Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy

NCT03253744
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasm
Interventions
18F-DCFPyL, Tumor Irradiation, Prostate + tumor irradiation
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 13, 2026, 10:36 PM EDT
Completed No phase listed Observational

Evaluation of Molecular Forms of PSA and Human Kallikrein 2 in a Cohort of Patients With Locally Resected Prostate Cancer But Biochemical Recurrence

NCT02070575
View directory record Official record
Conditions
Prostate Cancer
Interventions
blood draw
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
30 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 13, 2026, 10:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PSA-Activated PSA-PAH1 for Locally Recurrent Prostate Cancer

NCT00379561
View directory record Official record
Conditions
Prostate Cancer
Interventions
PSA-Activated PSA-PAH1
Drug
Lead sponsor
Sophiris Bio Corp
Industry
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2018 · Synced Sep 13, 2026, 10:36 PM EDT
Recruiting Phase 3 Interventional

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

NCT06952803
View directory record Official record
Conditions
Prostate Cancer
Interventions
Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
45
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 13, 2026, 10:36 PM EDT
Not listed Phase 1Phase 2 Interventional

Brachytherapy in Treating Patients With Recurrent Prostate Cancer

NCT00005939
View directory record Official record
Conditions
Prostate Cancer
Interventions
brachytherapy, phosphorus P32
Radiation
Lead sponsor
Center for Molecular Medicine
Other
Eligibility
21 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Garden City, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Sep 13, 2026, 10:36 PM EDT
Recruiting Early Phase 1 Interventional

Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients

NCT05045066
View directory record Official record
Conditions
Localized Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Locally Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma
Interventions
Cholecalciferol, Quality-of-Life Assessment, Biospecimen Collection
Dietary Supplement · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Scottsdale, Arizona • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 13, 2026, 10:36 PM EDT
Completed Phase 1 Interventional

Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer

NCT00482807
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, docetaxel, goserelin, intensity-modulated radiation therapy
Drug · Radiation
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 23, 2023 · Synced Sep 13, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

Ultrasound-Guided Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer Previously Treated With External-Beam Radiation Therapy

NCT00450411
View directory record Official record
Conditions
Prostate Cancer
Interventions
125-Iodine, 103-palladium
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
13
States / cities
Phoenix, Arizona • Fresno, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Sep 13, 2026, 10:36 PM EDT
Completed Phase 2 Interventional

An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy

NCT00686088
View directory record Official record
Conditions
Locally Recurrent Prostate Cancer
Interventions
PRX302
Drug
Lead sponsor
Sophiris Bio Corp
Industry
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
San Antonio, Texas • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2009 · Synced Sep 13, 2026, 10:36 PM EDT
Active, not recruiting Phase 2 Interventional

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, HER2-Positive Breast Carcinoma, Locally Advanced Breast Carcinoma, Locally Advanced Gastric Carcinoma, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Ovarian Carcinoma, Locally Advanced Pancreatic Carcinoma, Locally Advanced Prostate Carcinoma, Metastatic Breast Carcinoma, Metastatic Gastric Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Prostate Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Breast Carcinoma, Recurrent Gastric Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Talazoparib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Gainesville, Florida • Bethesda, Maryland • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 13, 2026, 10:36 PM EDT
Completed Phase 1Phase 2 Interventional

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

NCT03602079
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer, Salivary Gland Cancer, Salivary Gland Tumor, Salivary Gland Carcinoma, Salivary Gland Neoplasms, Lung Cancer, Colo-rectal Cancer, Rare Diseases, Solid Tumor, Recurrent Gastric Cancer, Recurrent Colon Cancer, Recurrent Breast Cancer, Head and Neck Cancer, Head and Neck Carcinoma, Bladder Cancer, Cervical Cancer, Liver Cancer, Bile Duct Cancer, Urologic Cancer, Pancreatic Cancer, Prostate Cancer, Recurrent Prostate Cancer, Rectal Cancer, Recurrent Ovarian Carcinoma, Recurrent Renal Cell Cancer, Rectal Cancer Stage II, Rectal Cancer Stage I, Rectal Cancer Stage III, Skin Cancer, Mouth Cancer, Lip Cancer Stage I, Tongue Cancer, Breast Neoplasm Malignant Primary, Larynx Cancer, Tonsil Cancer, Palate Cancer, Mucoepidermoid Carcinoma, Primary Peritoneal Carcinoma, Mucinous Adenocarcinoma Gastric, Mucinous Breast Cancer Recurrent, Cholangiocarcinoma
Interventions
A166
Drug
Lead sponsor
Klus Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
10
States / cities
Sarasota, Florida • Boston, Massachusetts • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Sep 13, 2026, 10:36 PM EDT
Terminated Phase 1 Interventional

Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate Cancer

NCT00005067
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions
motexafin lutetium, photodynamic therapy
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Sep 13, 2026, 10:36 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

NCT01050504
View directory record Official record
Conditions
Localized Renal Pelvis and Ureter Urothelial Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Recurrent Bladder Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Pelvis and Ureter Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v7, Stage IV Bladder Urothelial Carcinoma AJCC v7, Stage IV Prostate Cancer AJCC v7
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 13, 2026, 10:36 PM EDT
Active, not recruiting Phase 2 Interventional

Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers

NCT05722288
View directory record Official record
Conditions
Localized Prostate Carcinoma, Locally Advanced Cervical Carcinoma, Locally Advanced Rectal Carcinoma, Malignant Solid Neoplasm, Recurrent Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage IB Cervical Cancer FIGO 2018, Stage IB2 Cervical Cancer FIGO 2018, Stage II Prostate Cancer AJCC v8, Stage II Rectal Cancer AJCC v8, Stage IIA Cervical Cancer FIGO 2018, Stage IIB Cervical Cancer FIGO 2018, Stage III Prostate Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IIIC Cervical Cancer FIGO 2018, Stage IVA Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Informational Intervention, Quality-of-Life Assessment, Questionnaire Administration, Short-Term Fasting
Procedure · Other · Behavioral
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 13, 2026, 10:36 PM EDT
Completed Phase 1 Interventional

Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer

NCT00003704
View directory record Official record
Conditions
Cancer
Interventions
capecitabine, radiation therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
17
States / cities
Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Sep 13, 2026, 10:36 PM EDT
Recruiting Phase 2 Interventional

Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer

NCT07073794
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Locally Advanced Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions
Cancer Therapeutic Procedure, Health Care Delivery, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 13, 2026, 10:36 PM EDT
Completed Phase 1 Interventional

High Dose Rate Prostate Brachytherapy as Salvage for Locally Recurrent Prostate Cancer Previously Treated With External Beam Radiotherapy

NCT00604526
View directory record Official record
Conditions
Prostate Cancer
Interventions
High dose rate (HDR) brachytherapy using Iridium 192 radioactive seeds
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 85 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2016 · Synced Sep 13, 2026, 10:36 PM EDT
Completed Not applicable Interventional Results available

Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer

NCT00253708
View directory record Official record
Conditions
Cancer
Interventions
management of therapy complications, massage therapy, pain therapy, psychosocial assessment and care, quality-of-life assessment
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2017 · Synced Sep 13, 2026, 10:36 PM EDT
Completed Phase 2 Interventional

Leuprolide, Bicalutamide, and Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer After External-Beam Radiation Therapy

NCT00684905
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, leuprolide acetate, adjuvant therapy, neoadjuvant therapy, quality-of-life assessment, brachytherapy
Drug · Procedure · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 11, 2012 · Synced Sep 13, 2026, 10:36 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

HDR Brachytherapy, EBRT and STAD for the Treatment of Prostate Cancer

NCT03553602
View directory record Official record
Conditions
Prostate Cancer - Recurrent
Interventions
HDR Brachytherapy + EBRT + STAD
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 13, 2026, 10:36 PM EDT
Not listed Not applicable Interventional

A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)

NCT00772317
View directory record Official record
Conditions
Recurrent Prostate Cancer
Interventions
High Intensity Focused Ultrasound
Device
Lead sponsor
SonaCare Medical
Industry
Eligibility
40 Years to 85 Years · Male only
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
14
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Naples, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Sep 13, 2026, 10:36 PM EDT
Completed Phase 2 Interventional

Hormone Therapy Followed By Internal Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer

NCT00032006
View directory record Official record
Conditions
Prostate Cancer
Interventions
brachytherapy, radiation therapy
Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
8
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Urbana, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 13, 2026, 10:36 PM EDT
Terminated Phase 1 Interventional

Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to Radiation Therapy

NCT00788307
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ad5-CMV-NIS, Liothyronine Sodium, Reverse Transcriptase Polymerase Chain Reaction, laboratory biomarker analysis, Iodine I 131, Iodine I 123
Biological · Drug · Genetic + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 13, 2026, 10:36 PM EDT
Completed Phase 1 Interventional Results available

Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer

NCT02555397
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ad5-yCD/mutTKSR39rep-hIL12
Biological
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Sep 13, 2026, 10:36 PM EDT